Currently, Jesús is the Sr. director strategic innovation for the biopharma development division at Lonza, with a particular focus on disruptive technologies for bioprocessing, and more effective approaches to biopharmaceutical early development. Prior to this, Jesús was head of Lonza’s advanced protein technologies in Cambridge-UK, focusing on approaches to de-risk biopharmaceutical development. In 2002, he co-founded Zyentia Ltd, to design therapies for protein depositional disorders and tools to predict and remedy aggregation in biopharmaceuticals. He held various roles in the company, including CSO and acting-CEO until the acquisition of the AggreSolve™ business by Lonza in 2007. He was also co-founder and scientific advisor of Zapaloid Ltd, a company focused on the development of disease-modifying therapies against neurodegenerative disorders. Jesús has a Ph.D. in molecular biology from the Univ. Autónoma Madrid (CIB-CSIC). He completed several years of postdoctoral work at CBM-CSIC & University Complutense (Madrid) and subsequently held several
research fellowships at the Universities of Oxford and Cambridge, including Marie Curie & Wellcome Trust fellowships.